BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the company), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, has announced that it has entered into an agreement with funds managed by Sixth Street and funds managed by HealthCare Royalty, a business of KKR (HCRx and, together with Sixth Street, the purchasers) under which the purchasers have invested up to US$1 billion in newly issued convertible preferred equity of the company.
Latham & Watkins LLP represents BridgeBio in the transaction with a deal team led by partners Drew Capurro, Haim Zaltzman, Reza Mojtabaee-Zamani, and Eric Rice, with associates Jacob Walsh, Brice Stewart, and Robertson Dorsett. Advice was also provided on tax matters by partner Bora Bozkurt, with associate Farrah Yan; on antitrust matters by partners Josh Holian, Patrick English, Tomas Nilsson, and Jana Dammann de Chapto, with associates Jean Hyun and Amilia Kechagia; on FDA and healthcare matters by partners Nathan Beaton and Betty Pang, with assistance from associate Taylore Williams; on IP/licensing matters by counsel Robert Yeh; and on data privacy and cybersecurity matters by partner Heather Deixler.
